Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05636618 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contacts updated at 1 of 19 sitesv15
  2. Primary endpoint(s) modified Enrollment increased: 260 → 300 participants · Study sites: 17 to 19 · Eligibility criteria expanded, about 159 words · 3 morev14 Show 6 more changesShow less
    • Enrollment increased: 260 → 300 participants
    • Study sites: 17 to 19
    • Eligibility criteria expanded, about 159 words
    • Secondary endpoints: details revised at 3 of 5 entries
    • Study description shortened, about 1 word
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Site contacts updated at 1 of 17 sitesv13
  4. Study sites: 15 to 17v12
  5. Site contacts updated at 1 of 15 sitesv11
Show 9 earlier versionsHide 9 earlier versions
  1. Primary endpoints: 4 to 3 Enrollment target: 280 to 260 · Study sites: 13 to 15 · Interventions: [212Pb]VMT-α-NET (Drug), [212Pb]VMT-α-NET (Drug) to [203Pb]VMT-α-NET (Drug), [212Pb]VMT-α-NET (Drug) · 4 morev10 Show 7 more changesShow less
    • Enrollment target: 280 to 260
    • Study sites: 13 to 15
    • Interventions: [212Pb]VMT-α-NET (Drug), [212Pb]VMT-α-NET (Drug) to [203Pb]VMT-α-NET (Drug), [212Pb]VMT-α-NET (Drug)
    • Eligibility criteria expanded, about 51 words
    • Secondary endpoints: 4 to 5
    • Study description expanded, about 13 words
    • Study title expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 12 to 13v9
  3. Site details revised at 1 of 12 sitesv8
  4. Study sites: 11 to 12v7
  5. Site details revised at 1 of 11 sitesv6
  6. Enrollment target: 52 to 280 Primary completion date: Sep 30, 2026 to Nov 26, 2029 · Study sites: 8 to 11 · Completion date: Jan 31, 2028 to Dec 26, 2029 · 1 morev5 Show 4 more changesShow less
    • Primary completion date: Sep 30, 2026 to Nov 26, 2029
    • Study sites: 8 to 11
    • Completion date: Jan 31, 2028 to Dec 26, 2029
    • Study description expanded, about 54 words

    See this version in full on ClinicalTrials.gov ↗

  7. Study sites: 5 to 8v4
  8. Trial status: Not Yet Recruiting to Recruiting Study sites: 2 to 5 · Start date changed from estimate of Jul 1, 2023 to Sep 27, 2023 · Eligibility criteria revisedv3 Show 3 more changesShow less
    • Study sites: 2 to 5
    • Start date changed from estimate of Jul 1, 2023 to Sep 27, 2023
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  9. Start date: Mar 31, 2023 to Jul 1, 2023 Interventions: [212Pb]VMT-α-NET, (Drug) to [212Pb]VMT-α-NET (Drug), [212Pb]VMT-α-NET (Drug) · Study arms: 1 to 2v2 Show 2 more changesShow less
    • Interventions: [212Pb]VMT-α-NET, (Drug) to [212Pb]VMT-α-NET (Drug), [212Pb]VMT-α-NET (Drug)
    • Study arms: 1 to 2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
Trial Details
NCT Number NCT05636618
Lead Sponsor Perspective Therapeutics
Conditions Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma, Meningioma
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov